###begin article-title 0
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 54 58 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 167 172 <span type="species:ncbi:9606">human</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
Germline mutations in the tumor suppressor PTEN predispose human beings to breast cancer, and genetic and epigenetic alterations of PTEN are also detected in sporadic human breast cancer. Germline Pten mutations in mice lead to the development of a variety of tumors, but mammary carcinomas are infrequently found, especially in mice under the age of six months.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 109 113 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 120 135 <span type="species:ncbi:10090">transgenic mice</span>
To better understand the role of PTEN in breast tumor development, we have crossed Pten heterozygous mice to MMTV-Wnt-1 transgenic mice that routinely develop ductal carcinomas in the mammary gland. Female Wnt-1 transgenics heterozygous for Pten developed mammary tumors earlier than Wnt-1 transgenics that were wild type for Pten. In most tumors arising in Pten heterozygotes, the Pten wild-type allele was lost, suggesting that cells lacking Pten function have a growth advantage over cells retaining a wild type allele. Tumors with LOH contained high levels of activated AKT/PKB, a downstream target of the PTEN/PI3K pathway.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
An animal model has been developed in which the absence of Pten collaborates with Wnt-1 to induce ductal carcinoma in the mammary gland. This animal model may be useful for testing therapies specific for tumors deregulated in the PTEN/PI3K/AKT pathway.
###end p 6
###begin title 7
Introduction
###end title 7
###begin p 8
###xml 544 547 544 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 549 561 549 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1, BRCA2</italic>
###xml 563 579 563 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN/MMAC1/TEP1)</italic>
###xml 600 615 600 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(neu/ErbB2/HER2</italic>
###xml 617 627 617 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB1/EGFR</italic>
###xml 629 645 629 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRAD-1/cyclin D1</italic>
###xml 647 651 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdm2</italic>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc)</italic>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Cancer evolves from the accumulation of mutations and the deregulation of two classes of genes, oncogenes and tumor suppressor genes. The large majority of breast cancers arise in epithelia of the breast, and they are thought to evolve from hyperplasia with atypia to carcinoma in situ, invasive carcinoma, and, finally, metastatic disease. The molecular mechanisms leading to breast malignancies are unclear, but many genetic abnormalities and epigenetic factors have been implicated, including changes affecting known tumor suppressor genes (p53, BRCA1, BRCA2, PTEN/MMAC1/TEP1) and proto-oncogenes (neu/ErbB2/HER2, ErbB1/EGFR, PRAD-1/cyclin D1, Mdm2, and c-myc) [reviewed in ref. 1].
###end p 8
###begin p 9
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 26 37 26 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phosphatase</italic>
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tensin</italic>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
The gene product of PTEN (phosphatase and tensin homolog deleted from chromosome 10) is a lipid phosphatase that reverses the activities of phosphatidylinositol 3-kinase (PI3K) by dephosphorylating the D3 position of its lipid products, phosphatidylinositol-3, 4 bis-phosphate (PtdIns(3,4)P2), phosphatidylinositol-3,5 bis-phosphate (PtdIns(3,5)P2), and 3,4,5-tri-phosphate (PtdIns(3,4,5)P3) [2, 3], the elevated levels of which are linked to the transforming ability of PI3K [reviewed in ref. 4].
###end p 9
###begin p 10
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 708 709 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 711 712 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 834 835 826 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 837 838 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 recruit AKT (also known as protein kinase B [PKB]) to the membrane through the N-terminal pleckstrin homology (PH) domain of AKT [reviewed in ref. 5]. Membrane localization renders AKT permissive to phosphorylation by phosphatidyl inositol-dependent kinases, PDK1 and PDK2, at Thr308 within the activation loop and at Ser473 near the carboxyl terminus. Phosphorylation activates the kinase domain of AKT, which, in turn, phosphorylates target proteins on serine and threonine residues. Substrates of AKT include glycogen synthase kinase 3 (GSK3), p70/S6 kinase, BAD, Caspase 9, 4E-BP1, IkappaB kinase alpha and members of the Forkhead transcription family [reviewed in ref. 6, 7]. Constitutive membrane localization of AKT leads to its deregulated activation and can induce oncogenic transformation [8, 9].
###end p 10
###begin p 11
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT1</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT2</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT3</italic>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 10 15 <span type="species:ncbi:9606">human</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
All three human members of the AKT family are over-produced in various human cancers. AKT1 is over-expressed in gastric adenocarcinomas and breast cancer cell lines, AKT2 is amplified and over-expressed in pancreatic, ovarian, and breast cancers, and AKT3 is upregulated in estrogen receptor-deficient breast cancer and in androgen-independent prostate cell lines [reviewed in ref. 6].
###end p 11
###begin p 12
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Consistent with the role of PTEN as a lipid phosphatase, PTEN-deficient human and mouse cells have elevated levels of intracellular PtdIns(3,4,5)P3 [10, 11] and demonstrate constitutive activation of AKT in the absence of growth factors [12,13,14]. The relationship between components of this pathway is also conserved in flies and worms.
###end p 12
###begin p 13
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 597 601 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 99 105 <span type="species:ncbi:9606">humans</span>
###xml 370 375 <span type="species:ncbi:9606">human</span>
A germline mutation in PTEN is associated with multi-neoplastic, autosomally dominant syndromes in humans, such as Cowden disease and Bannayan-Zonana syndrome (also known as Bannayan-Riley-Ruvalcaba syndrome), and 20-50% of affected females in these families develop breast cancer [15,16,17]. The PTEN gene is also frequently deleted or mutated in a variety of sporadic human malignancies, such as glioblastoma and carcinomas of the prostate, endometrium and breast. Although somatic mutations in the gene have been detected in only about 1% of breast cancers, loss of heterozygosity (LOH) at the PTEN locus (10q23) is frequently found (approximately 40%), and 33% of breast tumors have no detectable, or reduced, levels of the protein product [18,19,20,21,22].
###end p 13
###begin p 14
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 571 576 <span type="species:ncbi:9606">human</span>
Three independent mouse lines carrying inactivating Pten mutations have been made [23,24,25]. All mice homozygous for these Pten mutations die during early embryogenesis. By 6 months of age, heterozygous mice develop tumors of the lymphoid system, colon, uterus, and adrenal medulla with very high penetrance, and tumors of the prostate and thyroid with lower penetrance. While benign mammary lesions, usually fibroadenomas, are found in female mice after 7 months of age, few animals develop ductal carcinomas [KP and RP, unpublished; 26], which account for over 85% of human breast cancers.
###end p 14
###begin p 15
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf-3</italic>
###xml 505 508 505 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 591 595 591 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 726 730 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 838 842 838 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 158 162 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 221 225 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
In an effort to develop a model for studying the effects of Pten inactivation in mammary oncogenesis, we have introduced an additional genetic alteration, an MMTV-Wnt-1 transgene, by breeding Pten heterozygotes [25] with MMTV-Wnt-1 transgenic (TG) mice [27]. Female mice harboring the Wnt-1 transgene develop extensive mammary hyperplasia early in life, and 50% of them develop mammary ductal carcinomas by 6 months of age [27]. This transgene has been shown to collaborate with Fgf-3 and inactivation of p53 to accelerate the appearance of mammary tumors [28, 30]. After a mutant allele of Pten was crossed into Wnt-1 TG mice, we found that ductal carcinomas appeared earlier than either alteration alone and that LOH at the Pten locus occurred in the majority of these tumors, suggesting a selective growth advantage in cells that lack Pten functions.
###end p 15
###begin title 16
Results
###end title 16
###begin p 17
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 550 558 550 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1 TG</italic>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 628 633 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 662 666 662 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 701 706 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 711 715 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 774 778 774 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 980 984 980 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 219 223 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 407 411 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 782 786 <span type="species:ncbi:10090">mice</span>
Wnt-1 TG mice have been used to assess the functions of a number of genetic lesions in breast carcinogenesis because tumors appear with predictable kinetics. The median age at which tumors are detected is 5-6 months in MMTV-Wnt-1 TG females [27, 28, 30, 31]. After one mutated allele of Pten was bred into this transgenic line, tumors appeared significantly earlier than in sibling females harboring only a MMTV-Wnt-1 transgene (P < 0.001, Fig. 1A). Fifty percent of Pten+/-, Wnt-1 TG female mice formed tumors by 3.5 months, 2.5 months earlier than Wnt-1 TG mice (Fig. 1A). While it took one year for the entire cohort (15) of Wnt-1 TG females with a wild type Pten background to develop tumors, all Wnt-1 TG, Pten+/- females showed tumors by 5 months of age. Five each of Pten+/- mice without a Wnt-1 transgene were monitored for 7 months and 10.5 months, but none developed any palpable mammary lesions. These observations differ from a recent report that one of the other two Pten+/- lines develops fibroadenomas and adenocarcinomas in the mammary tissue after 7 months of age [26]. The lack of a mammary phenotype in our studies could be due to differences in the targeting constructs, the genetic backgrounds, or even environmental agents.
###end p 17
###begin p 18
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
By one year of age, approximately 15% of Wnt-1 TG males have been reported to develop mammary tumors [27, 28, 31]. In our cross, one of the four tumors from Wnt-1 TG males, in an otherwise wild type background, was a mammary carcinoma; the other three tumors were salivary in origin, with a similar histopathology to the mammary lesion. The appearance of tumors was greatly accelerated in the Pten heterozygous background (Fig. 1B). Fifty percent of males developed tumors by 5.5 months of age, and all developed tumors within 10 months. As in the case of Wnt-1 TG male mice without Pten mutations, the majority of tumors (14/22) arose in the salivary tissue; only a small number of tumors (2/22) were mammary in origin, and, interestingly, some (6/22) were bilateral or unilateral muzzle tumors of epithelial origin, similar histopathologically to lesions found in mammary and salivary tissues.
###end p 18
###begin p 19
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 462 466 462 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
To determine if the wild type allele of Pten was inactivated in tumors arising in a Pten+/- background, 11 tumors from Wnt-1 TG, Pten+/- mice were examined for LOH by Southern hybridization. Seven tumors had lost the wild type Pten allele (see Fig. 2 for an example of the analysis). This result suggests that, in tumorigenesis, cells that lack a functional allele of Pten have a significant proliferative advantage over the cells that retain the normal copy of Pten.
###end p 19
###begin p 20
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1 TG</italic>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Histological examination showed that tumors from Wnt-1 TG mice, regardless of Pten status, were adenocarcinomas with cribriform, cystic and focal papillary growth patterns. However, 3 of the 6 tumors that were Wnt-1 TG, Pten +/- with LOH appeared to have a higher nuclear grade, more cellular stroma and a more infiltrative pattern compared to the tumors without a Pten defect (Fig. 3), suggesting a more aggressive phenotype.
###end p 20
###begin p 21
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 681 685 681 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 888 892 888 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 305 311 <span type="species:ncbi:9986">rabbit</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
In human cancer, a tumor suppressor gene can be inactivated by mutations, chromosomal loss, promoter silencing, and other means. To determine if the Pten protein was produced in Wnt-1 TG, Pten+/- tumors that did not undergo LOH, sections were analyzed using an immunohistochemical assay with a polyclonal rabbit antibody. Abundant amounts of Pten were detected in mammary ducts from wild type mice. Pten was detected, at reduced levels, in both hyperplastic ducts and mammary tumors that did not have LOH at the Pten allele (Fig. 4), suggesting that Pten was, indeed, made from the second allele. Similar low levels of Pten were also detected in mammary ductal epithelial cells in Pten heterozygous mice that did not have a Wnt-1 transgene, suggesting that the Wnt-1 transgene does not influence Pten expression. As expected, Pten was not detected in tumors that had undergone LOH at the Pten locus (Fig. 4E).
###end p 21
###begin p 22
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 784 788 784 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 814 819 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 824 828 824 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 878 884 878 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B &amp; C</xref>
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
Inactivation of Pten promotes membrane recruitment of AKT and its subsequent activation by phosphorylation at Ser473 and Thr308 [10, 11, 13]. All three human isoforms of AKT have been found to be deregulated in human breast cancer cells [32,33,34]. To determine if activated AKT was increased in tumors that had a Pten defect, these sections were stained using an antibody that specifically detects AKT1 phosphorylated at Ser 473 (and AKT2 and AKT3 phosphorylated at equivalent sites). Tumors that were Wnt-1 TG, Pten+/- with LOH displayed staining of phosphorylated AKT (Fig. 5A). Surprisingly, the staining was patchy, suggesting additional factors may be required for AKT activation. As expected, phosphorylated AKT was undetectable in hyperplastic ducts, in tumors from Wnt-1 TG, Pten+/+ mice, and tumors from Wnt-1 TG, Pten+/- mice that retained the wild type allele (Fig. 5B & C).
###end p 22
###begin p 23
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 500 504 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
Several apoptotic pathways may be inhibited upon activation of AKT, promoting maintenance and survival of tumor cells. Cellular proliferation may also be enhanced by activated AKT, which inhibits p27 and GSK-3 (leading to stabilization of cyclin D1) [35]. However, tumors from Wnt-1 TG, Pten+/+ mice have low apoptotic rates (40 +/- 16 per digital camera field using a 20x objective) and high proliferation rates (53% +/- 11). Neither apoptotic nor proliferation rates were affected by the status of Pten when measured by the TUNEL (terminal deoxynucleotidyltransferase-mediated UTP end labeling) assay, which labels the ends of fragmented DNA present in apoptotic cells, and immunohistochemical staining for Ki67, a cell proliferation marker (data not shown).
###end p 23
###begin p 24
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 319 328 319 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, Pten+/-</italic>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
Most Wnt-1 TG mice (38/49) developed only one palpable tumor regardless of Pten status. Fifty-three of 55 single sections from Pten+/+ glands that were free of a palpable mass did not show any lesions more advanced than ductal hyperplasia. However, at the time of sacrifice, the majority (50/56) of glands from Wnt-1 TG, Pten+/- mice had intra-ductal squamous lesions of various sizes (Fig. 3D). These squamous lesions were usually multi-focal and located both at the periphery of the adenocarcinomas and in other mammary glands free of adenocarcinomas.
###end p 24
###begin p 25
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 639 643 639 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
Since Pten mutations are usually found in advanced tumors, and the protein has been suggested to inhibit cell spreading, migration, and invasion [36, 37], it is possible that the tumors from Wnt-1 TG, Pten+/- mice may have a higher potential to metastasize than those from mice carrying a Wnt-1 transgene in a wild type Pten background. Wnt-1 TG mice occasionally show lymphoid or pulmonary metastasis [27], and serial sectioning of lung tissues from the animals reported here revealed microsocopic metastatic foci in two of five lungs from Wnt-1 TG mice bearing primary tumors 1.5-2.0 cm in size. However, Wnt-1 TG mice and the Wnt-1 TG, Pten+/- mice harbored metastatic foci at similar frequencies (5/10). (Statistical evaluation was not performed because the sample sizes were too small.)
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1 TG</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 582 586 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 633 637 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 715 719 715 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 911 915 911 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 936 941 936 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 1020 1024 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 1171 1173 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">Mice</span>
###xml 376 380 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
Mouse models are valuable research tools for the study of the molecular mechanisms of oncogenesis and for the testing and screening of cancer therapeutic agents targeted to specific oncogenic lesions. In order to produce such a model for studying the effects of Pten mutations in breast cancer, we have crossed Wnt-1 TG mice to mice heterozygous for Pten. Mice transgenic for MMTV-Wnt-1 and heterozygous for Pten developed mammary adenocarcinomas much earlier than mice carrying either lesion alone. The majority of tumors in Wnt-1 TG, Pten+/- mice had lost the wild type allele of Pten, suggesting that the complete inactivation of Pten function provides an additional growth advantage to these tumors. LOH at the Pten locus has recently been reported in mammary tumors arising in Pten heterozygous mice [26], but only 4% of the mice developed tumors before the age of 30 weeks, and, in our cross, none of the Pten+/- mice without the Wnt-1 transgene had a palpable mammary tumor before the age of 30 weeks. LOH at the Pten locus has also been reported in adrenal and lymphatic tumors, but not in uterine tumors and prostate lesions in Pten+/- mice [KP & RP, submitted; 38].
###end p 27
###begin p 28
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
Activated AKT was more abundant in tumors that were Wnt-1 TG, Pten +/- with LOH, as has been shown for uterine tumors in Pten heterozygous mice (KP, RP, submitted). The presence of areas unstained with antibody specific for phosphorylated AKT suggests that additional factors other than Pten may influence the activation of AKT.
###end p 28
###begin p 29
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
Neither apoptosis nor proliferation, as determined by the TUNEL assay and KI67 staining, was significantly different between tumors heterozygous for Pten (with or without LOH) and those without a Pten defect. This result may seem paradoxical since increased phosphorylated AKT, due to inactivation of Pten, suppresses apoptosis and promotes proliferation. However, tumors in Wnt-1 TG mice in a wild type Pten background already have highly suppressed apoptosis and accelerated proliferation rates, and any incremental changes, if present, may be difficult to detect with our current assays. Nonetheless, a seemingly minor difference in either apoptosis or proliferation could have a dramatic impact on tumor growth over time.
###end p 29
###begin p 30
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 457 474 457 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53, Brca1, Brca2</italic>
###xml 480 482 480 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb</italic>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 697 702 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-</italic>
###xml 881 886 881 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 1011 1017 1008 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc,</italic>
###xml 1022 1030 1019 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D</italic>
###xml 1104 1106 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 923 928 <span type="species:ncbi:9606">human</span>
###xml 1049 1054 <span type="species:ncbi:9606">human</span>
Accelerated appearance of mammary adenocarcinomas in the presence of a Pten mutation suggests a synergy between Pten inactivation and the Wnt-1 transgene. The apparent cooperation of these two genetic factors is further strengthened by our finding that the majority of tumors arising in a Pten+/- background have lost the wild type allele. To date, heterozygous inactivation of any of the other tumor suppressor genes implicated in breast cancer, including P53, Brca1, Brca2, and Rb, has failed to cooperate with Wnt-1 in promoting the appearance of mammary tumors [reviewed in ref. 39]. Therefore, it is possible that the signal pathway controlled by Pten is one of the preferred partners of the Wnt-1 pathway in cancer progression, although it remains possible that LOH at the Pten locus is more likely to occur than for the other alleles crossed into Wnt-1 TG mice. Even though Wnt-1 has not been directly implicated in human cancers, many components of the Wnt signaling pathway (such as beta-catenin, APC, c-myc, and cyclin D1) are involved in human tumors including breast cancer [reviewed in ref. 40].
###end p 30
###begin p 31
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 789 793 789 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
One of the goals of mouse modeling efforts is to provide an opportunity for pre-clinical testing of generalized or mechanism-specific therapeutics in a defined genetic setting. Many human breast tumors have reduced levels of PTEN, hence inhibitors of the cell signaling pathways affected by PTEN could be tested in the model we have developed. One such candidate is the rapamycin analog CCI779, which has been suggested to inhibit the AKT signaling pathway, probably through inhibition of mTOR (target of rapamycin), a potential target of AKT [reviewed in ref. 41]. CCI779 has been shown to have inhibitory effects on the growth of Pten-deficient tumors in the uterus and prostate in mice (KP & RP, submitted; M. Neshat & C. Sawyers, submitted). Since tumors arise rapidly after a copy of Pten is inactivated, and with predictable kinetics, this model may be useful for testing the efficacy of these therapies.
###end p 31
###begin p 32
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 494 502 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1 TG</italic>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
Results presented here and published earlier [15,16,17,18, 26] have clearly demonstrated the significant impact of Pten on mammary oncogenesis. Future testing will examine the tumorigenic effects caused by other kinds of genetic damage in the signaling pathways affected by Pten. The TVA-directed gene delivery system [reviewed in ref. 42] can be used to introduce viral vectors carrying genes encoding an activated form of PI3K, AKT, or candidate substrates for AKT into the mammary tissue of Wnt-1 TG mice. This would allow the testing of therapeutic interventions directed to specific steps of the signaling pathway regulated by Pten.
###end p 32
###begin title 33
Materials and methods
###end title 33
###begin title 34
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 34
###begin p 35
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 20 22 20 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 474 478 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">Mice</span>
MMTV-Wnt-1 TG mice [27] and those that carry a mutant allele of Pten [25] have been described. Male Wnt-1 TG mice (a mixture of FVB, SJL, and C57BL/6) were crossed with Pten heterozygous females (a mixture of C57BL/6 and 129SvJ) to generate all three genotypes used in this paper: Wnt-1 TG, Pten+/-; Wnt-1 TG, Pten +/+; and Pten+/-. Genotyping for the Wnt-1 transgene was done using PCR as described [27]; PCR using primers from the neo cassette was performed to detect the Pten knockout allele. Mice were monitored weekly for tumor formation by visual inspection and/or palpation; most tumors were found when they were approximately 0.5 cm. Most of tumors were harvested for further analysis when they were 1.5 cm in diameter. Tissues were fixed in 10% buffered formalin and paraffin-embedded. For histological survey, one H-E section per block was analyzed.
###end p 35
###begin title 36
Immunohistochemical staining and TUNEL assay
###end title 36
###begin p 37
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 505 511 <span type="species:ncbi:9986">Rabbit</span>
Formalin-fixed and paraffin-embedded sections were deparaffined and rehydrated in several changes of xylene, ethanol, and water. Antigen-unmasking was achieved by boiling the slides for 15 minutes in citrate buffer, pH 6.0, or 1 mM EDTA. Endogenous peroxidase activity was inactivated by a 5 minute incubation in 3% hydrogen peroxide, when needed. Immunohistochemical stainings were performed using Vector ABC kits (Vector Laboratories) following the manufacturer's recommendations and as described [25]. Rabbit antibodies against Pten, Ki67, and AKT phosphorylated at Ser 473 were from Neomarkers, Dako, and New England BioLabs, respectively. The TUNEL assay was performed as described [25].
###end p 37
###begin title 38
Southern hybridization
###end title 38
###begin p 39
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 204 206 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 294 298 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 300 302 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
DNAs extracted from tissues and tumors were digested with PstI, followed by electrophoresis, and blotted to Nylon+ membrane. Hybridization was done in ExpressHyb solution (Clontech) at 60degreesC using a 32P dCTP-labeled probe that was synthesized from a 0.9 Kb template located in intron 5 of Pten [25] using the RTS RadPrime DNA labeling system (Life Technologies). The probe was incubated with Cot-1 DNA (Life Technologies) at 70degreesC for 10 minutes before addition to the hybridization solution.
###end p 39
###begin title 40
Acknowledgements
###end title 40
###begin p 41
We thank Jennifer Doherty and Wendy Hively for technical assistance; Maria Merino and Carlos Cordon-Cardo for consultation on pathology samples; Osseh Saine, Marlon Scopio, and Jose Vargas for excellent animal care. YL is a recipient of the US Army Breast Cancer Research Program Fellowship Award.
###end p 41
###begin article-title 42
Molecular genetics of breast cancer progression.
###end article-title 42
###begin article-title 43
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
###end article-title 43
###begin article-title 44
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.
###end article-title 44
###begin article-title 45
Oncogenes and signal transduction.
###end article-title 45
###begin article-title 46
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
###end article-title 46
###begin article-title 47
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.
###end article-title 47
###begin article-title 48
Mechanisms and consequences of activation of protein kinase B/Akt.
###end article-title 48
###begin article-title 49
Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB.
###end article-title 49
###begin article-title 50
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
###end article-title 50
###begin article-title 51
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.
###end article-title 51
###begin article-title 52
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.
###end article-title 52
###begin article-title 53
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
###end article-title 53
###begin article-title 54
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.
###end article-title 54
###begin article-title 55
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
###end article-title 55
###begin article-title 56
###xml 56 64 <span type="species:ncbi:9606">patients</span>
The Cowden syndrome: a clinical and genetic study in 21 patients.
###end article-title 56
###begin article-title 57
Genetics of Cowden syndrome: through the looking glass of oncology.
###end article-title 57
###begin article-title 58
PTEN and inherited hamartoma-cancer syndromes [letter].
###end article-title 58
###begin article-title 59
Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.
###end article-title 59
###begin article-title 60
Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus.
###end article-title 60
###begin article-title 61
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.
###end article-title 61
###begin article-title 62
###xml 62 67 <span type="species:ncbi:9606">human</span>
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.
###end article-title 62
###begin article-title 63
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
###end article-title 63
###begin article-title 64
Pten is essential for embryonic development and tumour suppression.
###end article-title 64
###begin article-title 65
###xml 113 117 <span type="species:ncbi:10090">mice</span>
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
###end article-title 65
###begin article-title 66
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.
###end article-title 66
###begin article-title 67
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
###end article-title 67
###begin article-title 68
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.
###end article-title 68
###begin article-title 69
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice.
###end article-title 69
###begin article-title 70
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
###end article-title 70
###begin article-title 71
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
###end article-title 71
###begin article-title 72
###xml 0 25 <span type="species:ncbi:11757">Mouse mammary tumor virus</span>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4.
###end article-title 72
###begin article-title 73
Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF- I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells.
###end article-title 73
###begin article-title 74
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
###end article-title 74
###begin article-title 75
Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.
###end article-title 75
###begin article-title 76
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.
###end article-title 76
###begin article-title 77
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.
###end article-title 77
###begin article-title 78
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.
###end article-title 78
###begin article-title 79
The multiple roles of PTEN in tumor suppression.
###end article-title 79
###begin article-title 80
###xml 7 11 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer.
###end article-title 80
###begin article-title 81
Wnt signaling and cancer.
###end article-title 81
###begin article-title 82
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation.
###end article-title 82
###begin article-title 83
###xml 78 84 <span type="species:ncbi:10090">murine</span>
Development of a flexible and specific gene delivery system for production of murine tumor models.
###end article-title 83
###begin title 84
Figures and Tables
###end title 84
###begin p 85
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 584 588 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
Pten heterozygosity accelerates tumor appearance in Wnt-1 TG females (A) and males (B). Percentages of mice that were tumor-free, as determined by weekly visual inspection and/or palpation, were plotted against the age when tumors were found. Genotypes and sizes are as indicated. For the Pten+/- female group without the Wnt-1 transgene, 10 mice were monitored to 30 weeks of age; among the 10 mice, 5 were kept for another 15 weeks of age. (A) All mice showed at least one adenocarcinoma. (B) The Wnt-1 TG, Pten+/+ cohort (13) had 1 mammary and 3 salivary tumors, and the Wnt-1 TG, Pten+/- cohort (22) had 2 mammary, 6 muzzle, and 14 salivary tumors.
###end p 85
###begin p 86
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
Example of LOH analysis. Blots of tumor and tail DNAs, digested with PstI, were probed with a 32P labeled Pten probe. Two bands could be observed, representing wild type and mutant alleles, as indicated at the left. Genotypes of mice are shown at the top.
###end p 86
###begin p 87
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 74 78 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Representative H+E sections of mammary tumors from progeny females of the MMTV-Wnt-1 and Pten+/- cross. Sections were from tumors that were Wnt-1 TG+, Pten+/+ (A); Wnt-1 TG+, Pten+/- (B); and Wnt-1 TG+, Pten+/- with LOH (C and D). A 40x objective was used. Blue arrows indicate the smooth boundaries of tumors, red arrow marks the infiltrating front of the tumor, and white arrows label the highly cellular stroma. (D) shows a part of an intraductal squamous lesion.
###end p 87
###begin p 88
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 146 152 <span type="species:ncbi:9986">rabbit</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
Immunohistochemical staining for Pten. Sections of mammary glands (A, D) and tumors (B, C, E, F) were stained for Pten (A, B, D, E, F) or control rabbit Ig (C) and counterstained with hematoxylin. Genotypes of mice were Pten+/+ (A); Wnt-1 TG, Pten+/+ (B); and Wnt-1 TG, Pten+/- (C-F). (E) and (C, F) were from tumors with or without LOH, respectively. A 40x objective was used.
###end p 88
###begin p 89
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 122 128 <span type="species:ncbi:9986">rabbit</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
Immunohistochemical staining for phosphorylated Akt. Sections of tumors were stained for phospho-Akt (A, B, C) or control rabbit IgG (D) and counterstained with hematoxylin. Genotypes of mice were Wnt-1 TG+, Pten+/- (A, B); Wnt-1 TG+, Pten+/+ (C, D). (A) and (B) were from tumors with or without LOH, respectively. A 40x objective was used.
###end p 89

